Physician profile
Joshua P Raff
NPI 1689672362
$1,956.86
in general payments reported to CMS, 2019-2025
31 companies · $95.40 in 2025
The $95.40 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $111 · 2021: $161 · 2022: $535 · 2023: $899 · 2025: $95.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $260.57 | 2019-2023 | Lumakras, Kyprolis |
| Novartis Pharmaceuticals Corporation | $228.29 | 2021-2023 | |
| Janssen Biotech, INC. | $145.21 | 2019-2023 | Tecvayli, Talvey |
| Abbvie INC. | $124.30 | 2023 | |
| Celgene Corporation | $100.47 | 2022-2025 | Reblozyl |
| Pfizer INC. | $81.12 | 2022-2023 | |
| Incyte Corporation | $75.21 | 2022-2023 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $68.80 | 2022-2023 | Injectafer, Enhertu |
| Astrazeneca Pharmaceuticals LP | $64.66 | 2022-2025 | Lynparza, Imfinzi |
| Emd Serono, INC. | $61.50 | 2023 | Bavencio, Tepmetko |
| Karyopharm Therapeutics INC. | $59.78 | 2022-2023 | Xpovio |
| Gilead Sciences, INC. | $57.98 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $51.87 | 2019-2022 | |
| Aveo Pharmaceuticals, INC. | $46.11 | 2021-2022 | |
| Exelixis INC. | $45.79 | 2022-2023 | Cabometyx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $43.27 | 2019-2023 | Xarelto |
| Myriad Genetic Laboratories, INC. | $43.14 | 2023 | Myrisk |
| Genzyme Corporation | $40.17 | 2022-2023 | |
| Servier Pharmaceuticals LLC | $39.17 | 2023 | |
| Sobi, INC | $37.11 | 2025 | |
| Foundation Medicine, INC. | $35.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.90 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $28.79 | 2023 | Epkinly |
| Progenics Pharmaceuticals, INC. | $28.73 | 2023 | Pylarify |
| Coherus Oncology, INC. | $27.12 | 2022-2023 | |
| Novocure INC. | $26.30 | 2023 | Optune |
| Jazz Pharmaceuticals INC. | $24.81 | 2023 | |
| Genentech USA, INC. | $23.20 | 2023 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $21.52 | 2023 | Libtayo |
| Clovis Oncology, INC. | $19.79 | 2022 | |
| Tempus Ai, INC | $15.11 | 2025 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Raff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.